ROBOSENSE
3.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense , the world’s leading autonomous driving LiDAR perception solution provider , announced today that the solid-state LiDAR RS-LiDAR-M1Simple(Simple Sensor Version ) is now ready for customer delivery, priced at $1,898 . The new RS-LiDAR-M1Simple is less than half the size of the previous version, with dimensions of 4.3” x 1.9” x 4.7” (110mm x 50mm x 120mm), and is equipped with enhanced hardware performance virtually equal to the serial production version provided to OEMs. The main body design of this automotive-grade solid-state LiDAR is finalized and ready for shipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200103005139/en/
In addition, RoboSense will demonstrate the world’s first smart solid-state LiDAR, the RS-LiDAR-M1Smart (Smart Sensor Version), at CES 2020 in Las Vegas, Booth 6138, LVCC North Hall from Jan 7-10, 2020 with an on-vehicle public road test. The RS-LiDAR-M1Smart main body is embedded with an AI perception algorithm that fully takes advantage of LiDAR’s potential to transform conventional 3D LiDAR sensors to a full data analysis and comprehension system.
“The RS-LiDAR-M1 is an optimal choice for the serial production of self-driving cars, far superior to mechanical LiDAR. The sooner solid-state LiDAR is used, the sooner production will be accelerated to mass-market levels,” said Mark Qiu, RoboSense COO.
RS-LiDAR-M1 Family Features:
- 125 laser beams with exceptional performance: the RS-LiDAR-M1 has a field of view of 120°*25°, which is the MEMS solid-state LiDAR’s largest field of view among released products worldwide. RoboSense uses 905nm lasers with low cost, automotive grade and small size instead of expensive 1550nm lasers. At the same time, RoboSense continuously breaks ranging ability limits to 150m at 10% NIST target, which is also MEMS solid-state LiDAR’s longest detection range.
- World’s smallest MEMS solid-state LiDAR: one-tenth the size of conventional 64-beam mechanical LiDAR. The RS-LiDAR-M1 can be easily embedded in the car’s body while still maintaining the vehicle’s appearance intact.
- Reduced parts from hundreds to dozens in comparison to traditional mechanical LiDARs for lower cost, shorter production time, and large-scale production capacity .
- Modular design: the scalability and layout flexibility of the optical module lay the foundation for subsequent MEMS LiDAR products and support the customization of products for different application cases.
- Stable and reliable: RoboSense fully implemented IATF16949 quality management system and ISO26262 functional safety standards, combining ISO16750 test requirement and other automotive-grade reliability specifications to verify the RS-LiDAR-M1 series of products.
- All-weather: In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the standards, and the final mass-produced RS-LiDAR-M1 will adapt to all climatic and working conditions.
- Minimal wear and tear: as a solid-state LiDAR, the RS-LiDAR-M1 eliminates potential optoelectronic device failures due to mechanical rotation.
The RS-LiDAR-M1Smart is a comprehensive system with sensor hardware, AI point cloud algorithm, and chipsets, which provides an end-to-end customer environment perception solution. RoboSense’s powerful AI perception algorithm injects the sensor with structured semantic-level comprehensive information, focusing on the perception of moving objects.
For orders visit www.robosense.ai/buy or to contact a RoboSense account manager.
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, Samsung, ControlWorks, Aidrivers, and more. For more information, see the website at: http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005139/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom